First-in-class therapy for autoimmune disease
Artax is discovering small molecules that target Nck, a key cytoplasmic adapter protein, recently discovered to play a key role in T-cell signalling and activation.
The Artax approach has the potential to reduce auto-immunity without affecting the ability of the immune system to respond to an infectious challenge.
CEO Joseph Lobacki
Advent Contact Alan Walts
Advent invested in the Series B in 2015.
Private Companies
Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases
Press Release. Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases Phase 1 Findings Demonstrated that Investigational Agent…
Read More
Artax Biopharma Expands Company’s Scientific Advisory Board
Press Release. Company Welcomes James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D., Both Experts in T-Cell-Mediated Diseases. Cambridge, MA, November 15, 2022 - Artax Biopharma, Inc., a…
Read More
Artax Biopharma Closes Financing to Advance Clinical Stage First-in- Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Press Release. Close of $26 Million Funds Immunomodulation Candidate AX-158 Development Adds New Investors Eli Lilly and Company and Sound Bioventures Cambridge, MA, May 11, 2022 - Artax…
Read More
Artax Biopharma Announces First-in-Human Dosing in Phase 1 Clinical Trial for AX-158, Company’s First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Press Release. The Phase 1 Trial, Expected to Conclude in 2022, Will Evaluate Safety, Exposure, and Pharmacokinetics of AX-158 in Healthy Volunteers AX-158, a Novel, Oral Small Molecule Immunomodulating…
Read More
